2016-Year in Review: Top Advances in Management of Melanoma

2016 was a year of continued advances in the management of melanoma as a result of advances in precision medicine and immunotherapy. Trial results matured defining the role of BRAF inhibitors and combination therapy as a new standard of care for advanced disease and it was demonstrated that immunotherapy can improve the outcomes for earlier stage disease.

BRAF inhibitors turn off a genetic mutation called BRAF V600 found in about half of patients with advanced melanoma, which allows melanoma cells to grow uncontrollably. The combination of Cotellic® (cobimetinib) plus Zelboraf® (vemurafenib) was shown to improve overall survival for patients with advanced, BRAF (V600) mutation-positive melanoma and the combination consisting of Taflinar (dabrafenib) plus Mekinist (trametinib) significantly improved survival compared to those treated with single agent Taflinar only.

Yervoy® (ipilimumab) is a monoclonal antibody that targets CTLA4, found on the surface of T cells. CTLA4 is thought to inhibit immune responses. By targeting this molecule, Yervoy enhances the immune system’s response against tumor cells. Yervoy was demonstrated to improve survival in stage III melanoma patients who are at high risk of recurrence following complete surgical resection.

CancerConnect News coverage of advances in the management of melanoma included the following key developments in 2016:

2016 Melanoma Research News

Other 2016 Melanoma News

CURRENT MELANOMA NEWS

LEARNING MORE ABOUT MELANOMA

Knowledge is power. Are you facing a new diagnosis, recurrence, living with metastatic disease, or supporting a loved one through their cancer journey?

  • Sign up for monthly newsletters on melanoma here.
  • Get the facts about melanoma here.
  • Follow CancerConnect on Facebook and Twitter.

In Case You Missed What Happened Last Year: 2015 Melanoma Year in Review

2015 FDA News

2015 Melanoma Research News

Copyright © 2017 CancerConnect. All Rights Reserved.